IL257929B2 - Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy - Google Patents
Methods of treating multiple myeloma and plasma cell leukemia by t cell therapyInfo
- Publication number
- IL257929B2 IL257929B2 IL257929A IL25792918A IL257929B2 IL 257929 B2 IL257929 B2 IL 257929B2 IL 257929 A IL257929 A IL 257929A IL 25792918 A IL25792918 A IL 25792918A IL 257929 B2 IL257929 B2 IL 257929B2
- Authority
- IL
- Israel
- Prior art keywords
- allogeneic
- cells
- population
- specific
- human patient
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims 20
- 208000031223 plasma cell leukemia Diseases 0.000 title claims 9
- 208000034578 Multiple myelomas Diseases 0.000 title claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 title claims 5
- 238000000034 method Methods 0.000 title claims 5
- 238000002659 cell therapy Methods 0.000 title 1
- 230000000735 allogeneic effect Effects 0.000 claims 69
- 210000004027 cell Anatomy 0.000 claims 41
- 208000008383 Wilms tumor Diseases 0.000 claims 22
- 208000026448 Wilms tumor 1 Diseases 0.000 claims 22
- 102100022748 Wilms tumor protein Human genes 0.000 claims 22
- 101710127857 Wilms tumor protein Proteins 0.000 claims 22
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 10
- 238000003745 diagnosis Methods 0.000 claims 4
- 108700028369 Alleles Proteins 0.000 claims 3
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229940054136 kineret Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562216525P | 2015-09-10 | 2015-09-10 | |
| US201562220641P | 2015-09-18 | 2015-09-18 | |
| PCT/US2016/050857 WO2017044678A1 (en) | 2015-09-10 | 2016-09-09 | Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL257929A IL257929A (en) | 2018-05-31 |
| IL257929B1 IL257929B1 (en) | 2024-02-01 |
| IL257929B2 true IL257929B2 (en) | 2024-06-01 |
Family
ID=57068181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL257929A IL257929B2 (en) | 2015-09-10 | 2016-09-09 | Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190381098A1 (enExample) |
| EP (1) | EP3347028A1 (enExample) |
| JP (1) | JP6947720B2 (enExample) |
| KR (1) | KR20180048992A (enExample) |
| CN (1) | CN108348552A (enExample) |
| AU (1) | AU2016320877A1 (enExample) |
| CA (1) | CA2997757A1 (enExample) |
| HK (1) | HK1257882A1 (enExample) |
| IL (1) | IL257929B2 (enExample) |
| MX (1) | MX395106B (enExample) |
| RU (1) | RU2743381C2 (enExample) |
| TW (1) | TWI759270B (enExample) |
| WO (1) | WO2017044678A1 (enExample) |
| ZA (1) | ZA201801656B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12338458B2 (en) | 2017-05-25 | 2025-06-24 | Memorial Sloan Kettering Cancer Center | Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy |
| US11925663B2 (en) | 2017-10-23 | 2024-03-12 | Atara Biotherapeutics, Inc. | Methods of managing tumor flare in adoptive immunotherapy |
| EP3765602A1 (en) | 2018-03-14 | 2021-01-20 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line for adoptive cellular therapy |
| CN111643525A (zh) * | 2020-06-16 | 2020-09-11 | 济宁医学院 | 引发免疫排斥反应在肿瘤治疗中的应用及其方法 |
| CN113881632B (zh) * | 2021-09-29 | 2023-09-29 | 四川省医学科学院·四川省人民医院 | 一种提高dc细胞活性的细胞培养基及培养方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4932199A (en) * | 1998-07-31 | 2000-02-21 | Haruo Sugiyama | Cancer antigens based on tumor suppressor gene wt1 product |
| AR021849A1 (es) * | 1998-09-30 | 2002-08-07 | Corixa Corp | Composiciones y metodos para la inmunoterapia especifica de wt1 |
| KR101213015B1 (ko) * | 2003-11-05 | 2012-12-26 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드 |
| FR2931163B1 (fr) * | 2008-05-16 | 2013-01-18 | Ets Francais Du Sang | Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive |
| US9738872B2 (en) * | 2008-10-30 | 2017-08-22 | Yeda Research And Development Co. Ltd. | Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment |
| AU2013207669C1 (en) * | 2012-01-13 | 2018-05-31 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
-
2016
- 2016-09-09 JP JP2018512945A patent/JP6947720B2/ja not_active Expired - Fee Related
- 2016-09-09 RU RU2018112526A patent/RU2743381C2/ru active
- 2016-09-09 CA CA2997757A patent/CA2997757A1/en active Pending
- 2016-09-09 AU AU2016320877A patent/AU2016320877A1/en not_active Abandoned
- 2016-09-09 WO PCT/US2016/050857 patent/WO2017044678A1/en not_active Ceased
- 2016-09-09 KR KR1020187009368A patent/KR20180048992A/ko not_active Withdrawn
- 2016-09-09 US US15/758,566 patent/US20190381098A1/en not_active Abandoned
- 2016-09-09 CN CN201680064239.2A patent/CN108348552A/zh active Pending
- 2016-09-09 IL IL257929A patent/IL257929B2/en unknown
- 2016-09-09 MX MX2018002816A patent/MX395106B/es unknown
- 2016-09-09 EP EP16775897.8A patent/EP3347028A1/en not_active Withdrawn
- 2016-09-09 HK HK19100243.4A patent/HK1257882A1/zh unknown
- 2016-09-09 TW TW105129257A patent/TWI759270B/zh not_active IP Right Cessation
-
2018
- 2018-03-09 ZA ZA2018/01656A patent/ZA201801656B/en unknown
Non-Patent Citations (4)
| Title |
|---|
| A. G. CHAPUIS ET AL,, TRANSFERRED WT1-REACTIVE CD8+ T CELLS CAN MEDIATE ANTILEUKEMIC ACTIVITY AND PERSIST IN POST-TRANSPLANT PATIENTS, 27 February 2013 (2013-02-27) * |
| E. M. TYLER ET AL, WT1-SPECIFIC T-CELL RESPONSES IN HIGH-RISK MULTIPLE MYELOMA PATIENTS UNDERGOING ALLOGENEIC T CELL-DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANTATION AND DONOR LYMPHOCYTE INFUSIONS, 10 January 2013 (2013-01-10) * |
| R J O'REILLY ET AL,, T-CELL DEPLETED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTS AS A PLATFORM FOR ADOPTIVE THERAPY WITH LEUKEMIA SELECTIVE OR VIRUS-SPECIFIC T-CELLS, 3 June 2015 (2015-06-03) * |
| TSUBOI AKIHIRO ET AL,, WILMS TUMOR GENE WT1 PEPTIDE-BASED IMMUNOTHERAPY INDUCED A MINIMAL RESPONSE IN A PATIENT WITH ADVANCED THERAPY-RESISTANT MULTIPLE MYELOMA., 31 December 2007 (2007-12-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6947720B2 (ja) | 2021-10-13 |
| JP2018530534A (ja) | 2018-10-18 |
| MX395106B (es) | 2025-03-21 |
| TWI759270B (zh) | 2022-04-01 |
| CN108348552A (zh) | 2018-07-31 |
| MX2018002816A (es) | 2018-06-08 |
| US20190381098A1 (en) | 2019-12-19 |
| AU2016320877A1 (en) | 2018-04-19 |
| HK1257882A1 (zh) | 2019-11-01 |
| ZA201801656B (en) | 2022-12-21 |
| WO2017044678A1 (en) | 2017-03-16 |
| RU2018112526A (ru) | 2019-10-10 |
| RU2018112526A3 (enExample) | 2020-01-31 |
| TW201714619A (zh) | 2017-05-01 |
| IL257929A (en) | 2018-05-31 |
| RU2743381C2 (ru) | 2021-02-17 |
| EP3347028A1 (en) | 2018-07-18 |
| KR20180048992A (ko) | 2018-05-10 |
| IL257929B1 (en) | 2024-02-01 |
| CA2997757A1 (en) | 2017-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257929B2 (en) | Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy | |
| CL2017002481A1 (es) | Terapia de combinación del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte progamada 1 (pd 1) para el tratamiento del cáncer | |
| WO2019094642A8 (en) | T cell manufacturing compositions and methods | |
| EP4424326A3 (en) | Modified nk-92 cells for treating cancer | |
| EP4338804A3 (en) | Epinephrine spray formulations | |
| PH12020552135A1 (en) | Kdm1a inhibitors for the treatment of disease | |
| MX2022003039A (es) | Metodo de seleccion de donantes universales para identificar donantes de celulas nk. | |
| EP4529957A3 (en) | Methods for allogenic hematopoietic stem cell transplantation | |
| BR112018072701A2 (pt) | métodos de tratamento de leucemia mieloide aguda e mieloma múltiplo usando células exterminadoras naturais | |
| EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| MX2023001287A (es) | Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos. | |
| WO2014183033A3 (en) | G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal | |
| MX2020006944A (es) | Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer. | |
| EP4470615A3 (en) | Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof | |
| EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
| MX2021012258A (es) | Combinacion de chir99021 y acido valproico para tratar la perdida auditiva. | |
| WO2016019332A8 (en) | Method and apparatus for recovery of umbilical cord tissue derived regenerative cells and uses thereof | |
| BR112016028561A2 (pt) | composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo. | |
| MX2020010121A (es) | Compuestos con actividad antitumoral contra celulas de cancer que portan las mutaciones del exon 19 del receptor 2 del factor de crecimiento epidermico humano. | |
| EP4516354A3 (en) | Compositions and methods for controlled ovarian stimulation | |
| Morris et al. | Nitazoxanide is effective therapy for norovirus gastroenteritis after chemotherapy and hematopoietic stem cell transplantation (HSCT) | |
| WO2019241742A8 (en) | Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer | |
| SG11201810188VA (en) | Amelioration and treatment of perinatal brain damage with pluripotent stem cells | |
| Palladini et al. | High-dose pomalidomide and dexamethasone induce rapid responses in patients with AL amyloidosis exposed to alkylators, immune modulatory drugs, and proteasome inhibitors | |
| EA202090990A1 (ru) | Системы и способы получения в-клеток генетически модифицированных для экспрессии выбранных антител |